LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
448
via cnbc.comBusiness & Companies

Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

FROM THE WIRE · CNBC.COM

Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive late-stage result strengthens Lilly's growth outlook in obesity treatment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Lilly plans to file by year-end for US approval.
  2. 02The daily pill targets moderate-to-severe obstructive sleep apnea in adults with obesity.
  3. 03The late-stage trial showed the pill eases sleep apnea.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.